Tuesday, July 19, 2011

Exelixis business development boss leaves company

Exelixis Inc.’s head of business development, Fran Heller, left the drug developer Monday, the company said in a Securities and Exchange Commission filing Tuesday.
The news of Heller’s departure as executive vice president of business development comes on the heels of Bristol-Myers Squibb’s decision earlier this month to return a cancer drug to Exelixis (NASDAQ: EXEL). While the company said it would not continue research on that drug, XL-218, it has concentrated on another cancer drug that BMS gave back a year ago, cabozantinib, which the company could partner with a larger drug developer.

No comments:

Post a Comment